{"title":"LncRNA ABCA9-AS1 as a ceRNA Promotes Gastric Cancer Progression by Sponging miR-497-5p to Regulate KIF23 Expression.","authors":"Yiwen Wu, Yiniu Xia, Hanyu Liu, Shilin Wen, Keming Zhong, Qianwen Xiao, Zhou Wang, Xiaoyan Yang, Zhizhong Xie","doi":"10.2174/0115680096455467260703054748","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Long noncoding RNAs (lncRNAs) have emerged as important modulators in the molecular pathology of cancer. lncRNA ABCA9-AS1 is a newly identified lncRNA, and its role in gastric cancer has not yet been reported.</p><p><strong>Objective: </strong>To investigate the effects of lncRNA ABCA9-AS1 on the proliferation and metastasis of gastric cancer cells and to explore its role in the miR-497-5p/KIF23 signalling cascade.</p><p><strong>Methods: </strong>A gastric cancer-specific ceRNA network (lncRNA-miRNA-mRNA) was constructed using RNA-seq and miRNA-seq data from TCGA. qRT-PCR was used to detect the expression levels of the target genes in gastric cancer cells (AGS, HGC-27, MKN28) and human gastric mucosal epithelial cells (GES-1). Knockdown of lncRNA ABCA9-AS1 was achieved using specific siRNA, while overexpression of KIF23 was achieved using a pcDNA3.1-based overexpression plasmid. The proliferative capacity of gastric cancer cells was assessed using CCK-8 and colony formation assays. Cell migration and invasion were evaluated by Transwell migration and Matrigel invasion assays, respectively.</p><p><strong>Results: </strong>A gastric cancer-specific lncRNA-associated ceRNA network was constructed. qRT-PCR showed significant upregulation of lncRNA ABCA9-AS1 in gastric cancer cells (AGS, HGC-27, MKN28), with concomitant downregulation of miR-497-5p and upregulation of KIF23. In AGS cells, ABCA9-AS1 knockdown increased miR-497-5p expression and reduced KIF23 expression, while miR-497-5p mimics suppressed KIF23 expression. Functional assays confirmed that ABCA9-AS1 knockdown and miR-497-5p overexpression inhibited the proliferation, migration, and invasion of AGS cells. Conversely, KIF23 restoration or miR-497-5p inhibition reversed these effects, as did KIF23 co-expression with miR-497-5p mimics.</p><p><strong>Discussion: </strong>Our results highlight lncRNA ABCA9-AS1 as a novel and promising prognostic biomarker that promotes gastric cancer progression by acting as a ceRNA to modulate the miR-497-5p/KIF23 axis.</p><p><strong>Conclusion: </strong>lncRNA ABCA9-AS1 is aberrantly upregulated in gastric cancer. As a ceRNA, it sponges miR-497-5p to increase KIF23 expression and enhance the proliferation, migration, and invasion of gastric cancer cells.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096455467260703054748","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Long noncoding RNAs (lncRNAs) have emerged as important modulators in the molecular pathology of cancer. lncRNA ABCA9-AS1 is a newly identified lncRNA, and its role in gastric cancer has not yet been reported.
Objective: To investigate the effects of lncRNA ABCA9-AS1 on the proliferation and metastasis of gastric cancer cells and to explore its role in the miR-497-5p/KIF23 signalling cascade.
Methods: A gastric cancer-specific ceRNA network (lncRNA-miRNA-mRNA) was constructed using RNA-seq and miRNA-seq data from TCGA. qRT-PCR was used to detect the expression levels of the target genes in gastric cancer cells (AGS, HGC-27, MKN28) and human gastric mucosal epithelial cells (GES-1). Knockdown of lncRNA ABCA9-AS1 was achieved using specific siRNA, while overexpression of KIF23 was achieved using a pcDNA3.1-based overexpression plasmid. The proliferative capacity of gastric cancer cells was assessed using CCK-8 and colony formation assays. Cell migration and invasion were evaluated by Transwell migration and Matrigel invasion assays, respectively.
Results: A gastric cancer-specific lncRNA-associated ceRNA network was constructed. qRT-PCR showed significant upregulation of lncRNA ABCA9-AS1 in gastric cancer cells (AGS, HGC-27, MKN28), with concomitant downregulation of miR-497-5p and upregulation of KIF23. In AGS cells, ABCA9-AS1 knockdown increased miR-497-5p expression and reduced KIF23 expression, while miR-497-5p mimics suppressed KIF23 expression. Functional assays confirmed that ABCA9-AS1 knockdown and miR-497-5p overexpression inhibited the proliferation, migration, and invasion of AGS cells. Conversely, KIF23 restoration or miR-497-5p inhibition reversed these effects, as did KIF23 co-expression with miR-497-5p mimics.
Discussion: Our results highlight lncRNA ABCA9-AS1 as a novel and promising prognostic biomarker that promotes gastric cancer progression by acting as a ceRNA to modulate the miR-497-5p/KIF23 axis.
Conclusion: lncRNA ABCA9-AS1 is aberrantly upregulated in gastric cancer. As a ceRNA, it sponges miR-497-5p to increase KIF23 expression and enhance the proliferation, migration, and invasion of gastric cancer cells.
期刊介绍:
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.